IFP Advisors Inc cut its holdings in Eli Lilly and Company (NYSE:LLY) by 2.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,644 shares of the company’s stock after selling 1,079 shares during the quarter. IFP Advisors Inc’s holdings in Eli Lilly and were worth $3,477,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Airain ltd bought a new position in Eli Lilly and in the 2nd quarter worth about $567,000. Buckingham Asset Management LLC boosted its stake in Eli Lilly and by 21.3% in the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock worth $266,000 after purchasing an additional 568 shares in the last quarter. BSW Wealth Partners boosted its stake in Eli Lilly and by 0.6% in the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after purchasing an additional 27 shares in the last quarter. Sumitomo Life Insurance Co. boosted its stake in Eli Lilly and by 4.4% in the 2nd quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock worth $2,675,000 after purchasing an additional 1,370 shares in the last quarter. Finally, Mirador Capital Partners LP boosted its stake in Eli Lilly and by 5.3% in the 2nd quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock worth $1,011,000 after purchasing an additional 619 shares in the last quarter. 76.43% of the stock is currently owned by hedge funds and other institutional investors.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares in the company, valued at approximately $3,646,338.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The disclosure for this sale can be found here. Insiders have sold a total of 628,588 shares of company stock worth $53,399,536 in the last 90 days. Company insiders own 0.20% of the company’s stock.

Eli Lilly and Company (NYSE:LLY) opened at $86.45 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The stock has a market cap of $95,189.66, a PE ratio of 21.14, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. Eli Lilly and Company has a one year low of $67.22 and a one year high of $89.09.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.88 EPS. equities research analysts forecast that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th were paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.41%. The ex-dividend date of this dividend was Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is currently 98.58%.

A number of equities analysts recently issued reports on LLY shares. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 price target on shares of Eli Lilly and in a research note on Thursday, September 28th. Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the stock a “hold” rating in a research note on Friday, October 6th. Piper Jaffray Companies reiterated a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a research note on Friday, October 13th. Jefferies Group reiterated a “buy” rating and issued a $89.00 price target (down previously from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Finally, Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price target (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $90.25.

ILLEGAL ACTIVITY NOTICE: “IFP Advisors Inc Sells 1,079 Shares of Eli Lilly and Company (LLY)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/10/ifp-advisors-inc-sells-1079-shares-of-eli-lilly-and-company-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.